Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Recombinant Protein / Other Proteins

Recombinant Human RAD51D Protein, N-His

Catalog #:   YHB30401 Specific References (50) DATASHEET
Applications: ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Expression system: E. coli
Accession: O75771
Protein length: Thr79-Thr328
Overview

Catalog No.

YHB30401

Expression system

E. coli

Species

Homo sapiens (Human)

Protein length

Thr79-Thr328

Predicted molecular weight

28.79 kDa

Nature

Recombinant

Endotoxin level

Please contact with the lab for this information.

Purity

>90% as determined by SDS-PAGE.

Accession

O75771

Applications

ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress

Form

Lyophilized

Storage buffer

Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.

Reconstitution

Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.

Shipping

In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Alternative Names

DNA repair protein RAD51 homolog 4, R51H3, RAD51 homolog D, RAD51-like protein 3, TRAD, RAD51D, RAD51L3

Data Image
  • SDS-PAGE
    SDS-PAGE for Recombinant Human RAD51D protein
References

Clinicopathological Characteristics of Ovarian and Breast Cancer in PALB2, RAD51C, and RAD51D Germline Pathogenic Variant Carriers., PMID:40428378

5'UTR gene regions in germline DNA sequencing panels: lessons from the analysis of breast and ovarian cancer patients of Tatar and Bashkir ethnic origin., PMID:40419811

Identifying the germline variation spectrum and predisposition genes in Chinese ovarian cancer using whole exome sequencing., PMID:40405108

Impact of germline variants on breast and ovarian cancer risk in Japanese women: an original cohort study and meta-analysis., PMID:40403695

Genetic Features of Tumours Arising in the Context of Suspected Hereditary Cancer Syndromes with RAD50, RAD51C/D, and BRIP1 Germline Mutations, Results of NGS-Reanalysis of BRCA/MMR-Negative Families., PMID:40282418

Extracellular vesicles in lung donor plasma: Potential indicators of donor organ quality., PMID:40118141

Pathogenic germline variants in Chinese pancreatic adenocarcinoma patients., PMID:40044664

Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparib., PMID:39695768

PRMT5-regulated splicing of DNA repair genes drives chemoresistance in breast cancer stem cells., PMID:39695328

Comprehensive Clinical Genetics, Molecular and Pathological Evaluation Efficiently Assist Diagnostics and Therapy Selection in Breast Cancer Patients with Hereditary Genetic Background., PMID:39684258

Germline Variants in DNA Interstrand-Cross Link Repair Genes May Contribute to Increased Susceptibility for Serrated Polyposis Syndrome., PMID:39519399

Germline genetic variants in a case of familial cancer: RAD51D and four other co-segregated variants., PMID:39445568

RAD51 Paralogs and RAD51 Paralog Complexes BCDX2 and CX3 Interact with BRCA2., PMID:39416194

Homologous recombination deficiency gene panel analysis results in synchronous endometrial and ovarian cancers., PMID:39356959

What About the Others? Clinical Management of Gynecologic Cancer Risk in Patients With Moderate-Risk Hereditary Cancer Genes ( ATM , BRIP1 , RAD51C , RAD51D , and PALB2 )., PMID:39324947

Validation of the BOADICEA model for epithelial tubo-ovarian cancer risk prediction in UK Biobank., PMID:39294438

Mechanism of BCDX2-mediated RAD51 nucleation on short ssDNA stretches and fork DNA., PMID:39268578

Economic evaluation of extended panel analysis in cancer patients with historical NHS diagnostic germline genetic testing - A modeling study based on real-world data., PMID:39260602

Clinical Impact of Constitutional Genomic Testing on Current Breast Cancer Care., PMID:39242249

Universal Genetic Testing for Newly Diagnosed Invasive Breast Cancer., PMID:39226054

Screening of gastric cancer diagnostic biomarkers in the homologous recombination signaling pathway and assessment of their clinical and radiomic correlations., PMID:39206620

The Impact of Li-Fraumeni and Germline Retinoblastoma Mutations on Leiomyosarcoma Initiation, Outcomes, and Genetic Testing Recommendations., PMID:39150540

Four cancer cases with pathological germline variant RAD51D c.270_271dup., PMID:39117461

Extended panel testing in ovarian cancer reveals BRIP1 as the third most important predisposition gene., PMID:39096152

Alterations in the expression of homologous recombination repair (HRR) genes in breast cancer tissues considering germline BRCA1/2 mutation status., PMID:39080120

Multi-gene panel analysis in BRCA1/2-negative patients suspected of hereditary breast and ovarian cancer syndrome: Real-world data from a single institution., PMID:39077936

The pathologic and clinical outcomes of risk-reducing salpingo-oophorectomy in asymptomatic carriers of homologous recombination repair gene mutation., PMID:39028150

Population-based germline breast cancer gene association studies and meta-analysis to inform wider mainstream testing., PMID:38986768

Demographics and Clinical Decision Making in Patients with Germline Moderate Penetrance Non-BRCA Mutations in Breast Cancer Related Genes., PMID:38976158

Germline Mutational Landscape and Novel Targetable RAD51D Variant in Chinese Patients With Ovarian Cancer., PMID:38905575

Landscape of potential germline pathogenic variants in select cancer susceptibility genes in patients with adult-type ovarian granulosa cell tumors., PMID:38898688

Germline mutations of breast cancer susceptibility genes through expanded genetic analysis in unselected Colombian patients., PMID:38890714

Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian Cancer., PMID:38866043

Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial., PMID:38815151

Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis., PMID:38716772

Endometrial Cancer in a Family With RAD51D Gene Mutation., PMID:38661557

Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer., PMID:38648056

Exome sequencing identifies HELB as a novel susceptibility gene for non-mucinous, non-high-grade-serous epithelial ovarian cancer., PMID:38633804

Histologic patterns in prostatic adenocarcinoma are not predictive of mutations in the homologous recombination repair pathway., PMID:38278448

Human Fallopian Tube-Derived Organoids with TP53 and RAD51D Mutations Recapitulate an Early Stage High-Grade Serous Ovarian Cancer Phenotype In Vitro., PMID:38255960

Radiation-Induced Lymphopoenia and Treatment Outcome in Hereditary Breast Cancer Patients., PMID:38206774

Germline testing of BRCA1, BRCA2, PALB2 and CHEK2 c.1100delC in 1514 triple negative familial and isolated breast cancers from a single centre, with extended testing of ATM, RAD51C and RAD51D in over 400., PMID:38123987

Early-Onset Ovarian Cancer <30 Years: What Do We Know about Its Genetic Predisposition?, PMID:38069345

Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival., PMID:38041901

RAD51 paralogs synergize with RAD51 to protect reversed forks from cellular nucleases., PMID:37843130

High PGAP3 expression is associated with lymph node metastasis and low CD8+T cell in patients with HER2+ breast cancer., PMID:37839361

RAD51D Secondary Mutation-Mediated Resistance to PARP-Inhibitor-Based Therapy in HGSOC., PMID:37833926

Germline Sequencing Analysis to Inform Clinical Gene Panel Testing for Aggressive Prostate Cancer., PMID:37733366

Ovarian high-grade serous carcinoma with transitional-like (SET) morphology: a homologous recombination-deficient tumor., PMID:37673346

Finding significance: New perspectives in variant classification of the RAD51 regulators, BRCA2 and beyond., PMID:37651978

Datasheet
$ 313
Product specifications
100 μg 313 1 mg 1629

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Recombinant Human RAD51D Protein, N-His [YHB30401]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only